Abstract:Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): Biomedical Research Institute of Murcia (IMIB-Arrixaca) Introduction Hypertrophic cardiomyopathy (HCM) is the leading cause of sudden death in people under 35 years of age. (1) The variability of the phenotype together with its incomplete penetrance has been an obstacle to a complete understanding of the clinical spectrum and consequences of the disease. In recent years, there has been increasing interest in telomeric shortening and several authors have linked it to age-related diseases and HCM. (2, 3) Our aim was to study whether telomere length could affect the age at presentation and the severity of the HCM phenotype in genetic carriers. Methods Measurement of telomere length in circulating leukocytes (LTLc) was performed in 96 patients carrying a mutation in MYBPC3 causing HCM [58 affected (24 severely affected), 38 unaffected]. The variants included were c.2308+1G>A, p.Pro108Alafs*9, p.Arg891Alafs*160 and p.Glu258Lys, all considered founder mutations in our region. Peripheral venous blood samples were obtained from patients at the Inherited Heart Diseases Unit and stored at -80 oC after informed consent had been signed by all participants. For telomere length analysis, a telomeric restriction fragment (TRF) assay was performed using the TeloTAGGGTelomereLenghtAssay kit (Roche, 12209136001) according to the manufacturer's protocol with slight modifications. Results Our results show a lower LTLc in those affected patients with a more severe HCM phenotype compared to the affected and unaffected group (p=0.023) independently of age and sex, which are two variables that affect LTLc. Similarly, a shorter telomere length was associated with greater severity of the phenotype, with patients presenting a larger left atrial size (p=0.032), septal size (p=0.023) and greater obstruction (p=0.044). The presence of atrial fibrillation (p=0.039) and sudden death (p=0.024) was also higher in patients with shorter telomeres. Conclusions Telomere length is a variable that influences the expression of the phenotype in HCM patients carrying a MYBPC3 variant. This is an observation that supports the thesis of numerous publications linking HCM and other age-related diseases, sometimes called telomeropathies,(2) to telomere shortening. It has also been linked to non-hereditary conditions(3). This fact sheds some light on the complex phenotypic variability present in HCM, raising LTL as a promising prognostic biomarker of the disease, as has already been suggested by other authors.(4, 5, 6).Workflow in the telomere legth analysisClinical associations of LTLc

Telomere length and cardiovascular disease risk

17-Year Follow-Up of Association Between Telomere Length and All-Cause Mortality, Cardiovascular Mortality in Individuals with Metabolic Syndrome: Results from the NHANES Database Prospective Cohort Study

Telomere Length: A Cardiovascular Biomarker and a Novel Therapeutic Target

Telomere length as a biomarker for cerebrovascular diseases: current evidence

Short Telomeres and Prognosis of Hypertension in a Chinese Population.

Telomere Length: A Potential Biomarker for the Risk and Prognosis of Stroke

Precision Measurement of Telomere Length as a Future Guide to Improve CVD Interventions

Telomere Shortening in Aging,Coronary Heart Disease and Cerebrovascular Diseases

The Importance of Telomere Shortening for Atherosclerosis and Mortality

Telomere Length as a marker of biological aging: A critical review of recent literature.

An original biomarker for the risk of developing cardiovascular diseases and their complications: Telomere length

DNA methylation-based telomere length is more strongly associated with cardiovascular disease and long-term mortality than quantitative polymerase chain reaction-based telomere length: evidence from the NHANES 1999–2002

Cell-free plasma telomere length correlated with the risk of cardiovascular events using machine learning classifiers

The association between telomere length and diabetes mellitus: accumulated evidence from observational studies

Telomere length measurement as a clinical biomarker of aging and disease

Early biomarkers of disease in hypertrophic cardiomyopathy: does telomere length matter?

Telomere length and aging-related outcomes in humans: A Mendelian randomization study in 261,000 older participants

Telomere Length as a Marker of Cellular Aging Is Associated With Prevalence and Progression of Metabolic Syndrome

Less Than Ideal Cardiovascular Health is Associated with Shorter Leukocyte Telomere Length: the National Health and Nutrition Examination Surveys, 1999–2002

Telomere Length as a Marker of Biological Age: State-of-the-Art, Open Issues, and Future Perspectives

Telomere Length Variations in Aging and Age-Related Diseases